Haemonetics Acquires Vivasure Medical

January 12, 2026—Haemonetics Corporation announced the acquisition of Vivasure Medical Limited, an Ireland-based developer of technology for percutaneous vessel closure.

According to Haemonetics, Vivasure’s PerQseal Elite system is a sutureless, fully absorbable solution for structural heart and endovascular procedures. It uses a bioabsorbable patch to seal large-bore (up to 26 F) arteriotomies and venotomies from inside the vessel.

In 2025, Vivasure submitted a premarket approval application to the FDA for the PerQseal Elite arterial closure system and received European CE Mark approval for both arterial and venous indications. Results from the prospective, single-arm, multicenter ELITE arterial study demonstrated ease of use with no need for preclose, with 0% major complications at 30-day follow-up, and immediate median time to hemostasis, stated the press release.

According to Haemonetics, the acquisition includes an upfront cash payment of €100 million, or approximately €52 million net of the value of certain previous investments and other loans made by Haemonetics to Vivasure as well as other customary closing adjustments. Additionally, it includes up to €85 million in contingent consideration based on sales growth and the achievement of certain other milestones, also subject to adjustment based on the value of certain previous investments and loan amounts.